Market Overview

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Menlo Therapeutics Inc. – MNLO


Rosen Law Firm, a global investor rights law firm, announces it is
investigating potential securities claims on behalf of shareholders of
Menlo Therapeutics Inc. (NASDAQ:MNLO) resulting from allegations that
Menlo may have issued materially misleading business information to the
investing public.

On April 9, 2018, Menlo disclosed that its Phase 2 clinical trial of
serlopitant for the treatment of pruritus in adults and adolescents with
a history of atopic dermatitis did not meet its primary or key secondary
efficacy endpoints. There was no statistically significant difference
demonstrated between patients treated with serlopitant and patients
treated with the placebo. On this news, Menlo's stock fell $27.05 per
share or over 76% to close at $8.17 on April 9, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Menlo investors. If you purchased shares of Menlo please
visit the firm's website at
to join the class action. You may also contact Phillip Kim or Zachary
Halper of Rosen Law Firm toll free at 866-767-3653 or via email at

Follow us for updates on LinkedIn:
or on Twitter:

Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class
Action Services for number of securities class action settlements in
2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View Comments and Join the Discussion!